Portal hypertension secondary to 90Yttrium microspheres: an unknown complication.
Ayav
Ahmet
A
Habib
Nagy
N
Jiao
Long R
LR
D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D006975:Hypertension, Portal / Q000139:chemically induced*; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy; D008297:Male; D008863:Microspheres; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D019275:Radiopharmaceuticals / Q000009:adverse effects*; D015021:Yttrium Radioisotopes / Q000009:adverse effects
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil